Researchers from Taiwan have found that Metformin, a common drug used to treat type 2 diabetes may have an effect of lowering the possibility of developing a disease leading to blindness.
The American Academy of Ophthalmology (AAO) based in San Francisco-based academy said diabetic patients using the medication have a significant lower rate of developing age-related macular degeneration (AMD), one of the leading causes of blindness in Americans aged 50 or above.
The research finding was disclosed at the AAO 122nd Annual Meeting being held in Chicago from Oct. 27. The meeting will end tomorrow Oct. 30.
The researchers studied the statistics of the health insurance research database in Taiwan from a period spanning from 2001 and 2013 and found that 45,524 type 2 diabetes patients who took metformin have better chances to avoid suffering AMD that affects about 2.1 million people in the United States.